Study of afimkibart for active Crohn's disease
Treatments studied
Part of Digestive system, Immune system & allergy clinical trials.
This trial tests a new medicine called afimkibart for people with moderately to severely active Crohn's disease that has not responded well to other treatments. It aims to see if the medicine can safely reduce inflammation and improve symptoms.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a confirmed diagnosis of Crohn's disease.
- Your Crohn's disease must be moderately to severely active.
- You must weigh at least 40 kilograms (about 88 pounds).
- You must have tried at least one other Crohn's treatment and it did not work well enough or caused side effects.
- If you can get pregnant or father a child, you must agree to use effective birth control during the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests an experimental drug called afimkibart for people with moderate to severe Crohn's disease who haven't responded well to other treatments. The goal is to see if the drug can help control symptoms and reduce inflammation over time.
This trial tests a medicine called afimkibart for children with moderately to severely active Crohn's disease. It aims to see how well the drug works and how safe it is when used for both starting and ongoing treatment.
This trial tests a new medicine called tulisokibart for people with moderate to severe Crohn's disease. The medicine may help reduce inflammation and improve symptoms. It is for those who have not had success with other treatments.
This trial tests new targeted therapies for adults with moderate to severe Crohn's disease that hasn't improved with standard treatments. The goal is to see if these drugs can reduce inflammation and improve symptoms.
This study tests advanced treatments for people with moderate to severe Crohn's disease or ulcerative colitis who haven't responded to at least one previous therapy. It aims to find better options for managing these conditions.
This study tests a new medicine called afimkibart for people with moderate to severe ulcerative colitis who have not responded well to other treatments. The goal is to see if it can help control symptoms and improve quality of life.
Hear when a new Moderately to Severely Active Crohns Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.